-
Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. Lancet (IF 98.4) Pub Date : 2024-09-13
BACKGROUND Antimicrobial resistance (AMR) poses an important global health challenge in the 21st century. A previous study has quantified the global and regional burden of AMR for 2019, followed with additional publications that provided more detailed estimates for several WHO regions by country. To date, there have been no studies that produce comprehensive estimates of AMR burden across locations
-
Global burden of antimicrobial resistance and forecasts to 2050. Lancet (IF 98.4) Pub Date : 2024-09-13 Samuel Kariuki
-
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet (IF 98.4) Pub Date : 2024-09-13 Michael J Morris,Daniel Castellano,Ken Herrmann,Johann S de Bono,Neal D Shore,Kim N Chi,Michael Crosby,Josep M Piulats,Aude Fléchon,Xiao X Wei,Hakim Mahammedi,Guilhem Roubaud,Hana Študentová,James Nagarajah,Begoña Mellado,Álvaro Montesa-Pino,Euloge Kpamegan,Samson Ghebremariam,Teri N Kreisl,Celine Wilke,Katja Lehnhoff,Oliver Sartor,Karim Fizazi,
BACKGROUND [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of 177Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer
-
177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot. Lancet (IF 98.4) Pub Date : 2024-09-13 Joaquin Mateo,Amado J Zurita
-
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (IF 98.4) Pub Date : 2024-09-13 Domenica Lorusso,Yang Xiang,Kosei Hasegawa,Giovanni Scambia,Manuel Leiva,Pier Ramos-Elias,Alejandro Acevedo,Jakub Cvek,Leslie Randall,Andrea Juliana Pereira de Santana Gomes,Fernando Contreras Mejía,Limor Helpman,Hüseyin Akıllı,Jung-Yun Lee,Valeriya Saevets,Flora Zagouri,Lucy Gilbert,Jalid Sehouli,Ekkasit Tharavichitkul,Kristina Lindemann,Nicoletta Colombo,Chih-Long Chang,Marketa Bednarikova,Hong Zhu
BACKGROUND At the first interim analysis of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, the addition of pembrolizumab to chemoradiotherapy provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with locally advanced cervical cancer. We report the overall survival results from the second interim analysis of this study. METHODS Eligible
-
Hope emerging in the locally advanced cervical cancer landscape. Lancet (IF 98.4) Pub Date : 2024-09-13 Christine Gennigens
-
-
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (IF 98.4) Pub Date : 2024-09-12 Jonathan D Spicer,Marina C Garassino,Heather Wakelee,Moishe Liberman,Terufumi Kato,Masahiro Tsuboi,Se-Hoon Lee,Ke-Neng Chen,Christophe Dooms,Margarita Majem,Ekkehard Eigendorff,Gastón L Martinengo,Olivier Bylicki,Delvys Rodríguez-Abreu,Jamie E Chaft,Silvia Novello,Jing Yang,Ashwini Arunachalam,Steven M Keller,Ayman Samkari,Shugeng Gao,
BACKGROUND At the first interim analysis of the KEYNOTE-671 trial, adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved event-free survival in participants with early-stage non-small-cell lung cancer (NSCLC). We report overall survival and health-related quality of life outcomes from the second interim analysis. METHODS KEYNOTE-671 was a global phase 3 trial done at
-
Improved survival for patients with lung cancer treated with perioperative immunotherapy. Lancet (IF 98.4) Pub Date : 2024-09-12 Carolyn J Presley,Dwight H Owen
-
Direct-to-consumer medical testing: an industry built on fear Lancet (IF 98.4) Pub Date : 2024-09-12 The Lancet
-
BMA members oppose its stance on the Cass Review Lancet (IF 98.4) Pub Date : 2024-09-12 Jacqui Thornton
-
-
Health impacts of fentanyl agreement questioned Lancet (IF 98.4) Pub Date : 2024-09-12 Udani Samarasekera
-
Offline: Breaking the conformity of global health Lancet (IF 98.4) Pub Date : 2024-09-12 Richard Horton
-
-
-
Techquity: digital pathways to reach all people for medical research Lancet (IF 98.4) Pub Date : 2024-09-12 Julia Moore Vogel, Vik Kheterpal, Eric J Topol
-
-
Catheter ablation for atrial fibrillation, atrio-oesophageal fistula, cerebral air embolism, and hyperbaric oxygen therapy Lancet (IF 98.4) Pub Date : 2024-09-12 Renaud Prével MD, Prof Alexandre Boyer MD, Prof Didier Gruson MD, Arthur Orieux MD
-
Beyond bacteria: the growing threat of antifungal resistance Lancet (IF 98.4) Pub Date : 2024-09-12 Norman van Rhijn, Sevtap Arikan-Akdagli, Justin Beardsley, Felix Bongomin, Arunaloke Chakrabarti, Sharon C-A Chen, Tom Chiller, Arnaldo Lopes Colombo, Nelesh P Govender, Ana Alastruey-Izquierdo, Sarah E Kidd, Michaela Lackner, Ruoyu Li, Ferry Hagen
-
Demanding attention to self-medication with antibiotics Lancet (IF 98.4) Pub Date : 2024-09-12 Umadevi Subramanian, Baskar Venkidasamy
-
Antimicrobial resistance in carceral settings Lancet (IF 98.4) Pub Date : 2024-09-12 Samuel Wilk, Jacinda C Abdul-Mutakabbir, Shira Doron, Christina Yen, Justin Berk, Alysse Wurcel
-
Antimicrobial use at end of life: a missing link in public health discourse Lancet (IF 98.4) Pub Date : 2024-09-12 Shila Pandey, Renee Wisniewski, Tiffanny Newman, Susan K Seo, William E Rosa
-
A call for antibiotic stewardship initiatives for dentistry in India Lancet (IF 98.4) Pub Date : 2024-09-12 Deepavalli Arumuganainar
-
Antimicrobial resistance in paediatric blast and crush injuries Lancet (IF 98.4) Pub Date : 2024-09-12 Emily Mayhew, Anthony Bull, Sumudith Jayasuriya
-
Bayesian statistics for clinical research Lancet (IF 98.4) Pub Date : 2024-09-12 Ewan C Goligher MD, Anna Heath PhD, Michael O Harhay PhD
Frequentist and Bayesian statistics represent two differing paradigms for the analysis of data. Frequentism became the dominant mode of statistical thinking in medical practice during the 20th century. The advent of modern computing has made Bayesian analysis increasingly accessible, enabling growing use of Bayesian methods in a range of disciplines, including medical research. Rather than conceiving
-
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial Lancet (IF 98.4) Pub Date : 2024-09-10 Richard M Bergenstal MD, Ruth S Weinstock MD, Prof Chantal Mathieu MD, Yukiko Onishi MD, Vishali Vijayanagaram MS, Michelle L Katz MD, Molly C Carr MD, Annette M Chang MD
Insulin efsitora alfa (efsitora) is a once-weekly basal insulin. This phase 3 study aimed to assess the efficacy and safety of efsitora compared with insulin degludec (degludec) in adults with type 1 diabetes.
-
Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies Lancet (IF 98.4) Pub Date : 2024-09-09 Natalie I Mazur MD PhD, Mauricio T Caballero MD MSc, Marta C Nunes PhD
The global burden of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in young children is high. The RSV prevention strategies approved in 2023 will be essential to lowering the global disease burden. In this Series paper, we describe clinical presentation, burden of disease, hospital management, emerging therapies, and targeted prevention focusing on developments and groundbreaking
-
A call for global solidarity and rapid action to control mpox Lancet (IF 98.4) Pub Date : 2024-09-09 Jean B Nachega, Jean‑Jacques Muyembe‑Tamfum, Francine Ntoumi, Placide Mbala‑Kingebeni, Alimuddin Zumla
-
Antimicrobial resistance at a crossroads: the cost of inaction Lancet (IF 98.4) Pub Date : 2024-09-09 Michael Craig, Daniel Jernigan, Kayla Laserson, Stefanie McBride, Jessica Fairbanks, Dawn Sievert, Paige A Armstrong, Heather Ewing Ogle, Howard Zucker
-
Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children Lancet (IF 98.4) Pub Date : 2024-09-09 Clint Pecenka PhD, Erin Sparrow DrPH, Daniel R Feikin MD, Padmini Srikantiah MD, Delese Mimi Darko PhD, Eric Karikari-Boateng MS, Ranju Baral PhD, Carla Vizzotti MD, Analia Rearte MSc, Rose Jalang'o MBChB, Jessica A Fleming PhD, Prof Federico Martinón-Torres MD PhD, Prof Ruth A Karron MD
The search for safe and efficacious products to prevent severe respiratory syncytial virus (RSV) disease in young infants has lasted more than 60 years. In high-income and middle-income countries, two new products have been authorised: an RSV monoclonal antibody for administration to infants (nirsevimab) and an RSV prefusion F maternal vaccine (RSVpreF [Pfizer, Puurs, Belgium]) for administration to
-
USA pledges $558 million for maternal mortality crisis. Lancet (IF 98.4) Pub Date : 2024-09-07 Bryant Furlow
-
India facing largest Chandipura virus outbreak in 20 years. Lancet (IF 98.4) Pub Date : 2024-09-07 Sharmila Devi
-
The global blood donation index: an imperfect measure of transfusion need. Lancet (IF 98.4) Pub Date : 2024-09-07 Jeremy W Jacobs,Imelda Bates,Claudia S Cohn,Nabajyoti Choudhury,Shirley Owusu-Ofori,Hans Vrielink,Eshan U Patel,Silvano Wendel,Aaron A R Tobian,Evan M Bloch
The optimum number of units of blood and the associated number of blood donors required to meet a given population's needs remain undetermined globally. Typically, a whole blood donation rate of ten donations per 1000 population, at a minimum, is necessary to meet a country's blood needs. This rate is attributed to a WHO recommendation that 1% of a given country's population should donate blood to
-
Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study. Lancet (IF 98.4) Pub Date : 2024-09-07 Paul Yang,Laura P Pardon,Allen C Ho,Andreas K Lauer,Dan Yoon,Shannon E Boye,Sanford L Boye,Alejandro J Roman,Vivian Wu,Alexandra V Garafalo,Alexander Sumaroka,Malgorzata Swider,Iryna Viarbitskaya,Tomas S Aleman,Mark E Pennesi,Christine N Kay,Kenji P Fujita,Artur V Cideciyan
BACKGROUND Leber congenital amaurosis 1 (LCA1), caused by mutations in GUCY2D, is a rare inherited retinal disease that typically causes blindness in early childhood. The aim of this study was to evaluate the safety and preliminary efficacy of ascending doses of ATSN-101, a subretinal AAV5 gene therapy for LCA1. METHODS 15 patients with genetically confirmed biallelic mutations in GUCY2D were included
-
Congenital syphilis in a 2-month-old infant during Japanese outbreak. Lancet (IF 98.4) Pub Date : 2024-09-07 Tomoaki Hirate,Kaori Kanda,Yumi Ohshima,Kunihiro Shinoda,Nobuyuki Tetsuka
-
Christian Happi: strengthening Africa's capacity in genomics. Lancet (IF 98.4) Pub Date : 2024-09-07 Aarathi Prasad
-
Polygenic risk scores for genomics and population screening. Lancet (IF 98.4) Pub Date : 2024-09-07 Sarah L Perrott,Siddhartha P Kar
-
Violating independence assumption in medical statistics. Lancet (IF 98.4) Pub Date : 2024-09-07 Georgios D Panos
-
Perinatal risk in India's Scheduled Tribes. Lancet (IF 98.4) Pub Date : 2024-09-07 Taranand Singh,Dinesh Kumar
-
Gene therapy in the early stages of retinal degeneration. Lancet (IF 98.4) Pub Date : 2024-09-07 Robert E MacLaren
-
-
The structural roots of violence against female health workers. Lancet (IF 98.4) Pub Date : 2024-09-07 The Lancet
-
The need for point-of-care tests for mpox. Lancet (IF 98.4) Pub Date : 2024-09-06 Ranu S Dhillon,Abraar Karan,Devabhaktuni Srikrishna,Jean-Vivien Mombouli
-
Advancing the economics of health for all Lancet (IF 98.4) Pub Date : 2024-09-05 Mariana Mazzucato, Tedros Adhanom Ghebreyesus
-
A crisis of safety: female health-care workers in India need reforms Lancet (IF 98.4) Pub Date : 2024-09-03 Gururaj Arakeri, Vishal Rao, Shankargouda Patil
-
Addressing global gun violence: a Lancet Commission on Global Gun Violence and Health. Lancet (IF 98.4) Pub Date : 2024-09-03 Adnan A Hyder,Lorena Barberia,
-
Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea Lancet (IF 98.4) Pub Date : 2024-09-02 Prof Sung-Jin Hong MD, Seung-Jun Lee MD, Sang-Hyup Lee MD, Prof Jong-Young Lee MD, Prof Deok-Kyu Cho MD, Prof Jin Won Kim MD, Prof Sang Min Kim MD, Prof Seung-Ho Hur MD, Prof Jung Ho Heo MD, Prof Ji-Yong Jang MD, Prof Jin Sin Koh MD, Prof Hoyoun Won MD, Prof Jun-Won Lee MD, Prof Soon Jun Hong MD, Prof Dong-Kie Kim MD, Prof Jeong Cheon Choe MD, Prof Jin Bae Lee MD, Prof Soo-Joong Kim MD, Prof Tae-Hyun
Despite the detailed imaging information provided by optical coherence tomography (OCT) during percutaneous coronary intervention (PCI), clinical benefits of this imaging technique in this setting remain uncertain. The aim of the OCCUPI trial was to compare the clinical benefits of OCT-guided versus angiography-guided PCI for complex lesions, assessed as the rate of major adverse cardiac events at
-
Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial Lancet (IF 98.4) Pub Date : 2024-09-02 Prof Chao Gao PhD, Xingqiang He MD, Prof Fan Ouyang PhD, Prof Zhihui Zhang PhD, Prof Guidong Shen PhD, Prof Mingxing Wu PhD, Prof Ping Yang PhD, Prof Likun Ma PhD, Prof Feng Yang PhD, Prof Zheng Ji PhD, Prof Hua Wang PhD, Prof Yanqing Wu PhD, Prof Zhenfei Fang PhD, Prof Hong Jiang PhD, Prof Shangyu Wen PhD, Prof Yi Liu PhD, Prof Fei Li PhD, Prof Jingyu Zhou PhD, Bin Zhu PhD, Yunpeng Liu MD, Ruining
The long-term impact of drug-coated balloon (DCB) angioplasty for the treatment of patients with de novo coronary artery lesions remains uncertain. We aimed to assess the non-inferiority of DCB angioplasty with rescue stenting to intended drug-eluting stent (DES) deployment for patients with de novo, non-complex coronary artery lesions. REC-CAGEFREE I was an open-label, randomised, non-inferiority
-
Optical coherence tomography imaging for complex percutaneous coronary intervention Lancet (IF 98.4) Pub Date : 2024-09-02 Mamas A Mamas, Gary S Mintz
-
Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up Lancet (IF 98.4) Pub Date : 2024-09-02 Prof Holger Thiele MD, Prof Jacob E Møller MD PhD, Prof Jose P S Henriques MD PhD, Margriet Bogerd MD, Prof Melchior Seyfarth MD, Prof Daniel Burkhoff MD PhD, Prof Petr Ostadal MD PhD, Prof Richard Rokyta MD, Prof Jan Belohlavek MD, Prof Steffen Massberg MD, Marcus Flather MD, Matthias Hochadel PhD, Steffen Schneider PhD, Prof Steffen Desch MD, Anne Freund MD, Hans Eiskjær MD, Prof Norman Mangner MD
Percutaneous active mechanical circulatory support (MCS) devices are being increasingly used in the treatment of acute myocardial infarction-related cardiogenic shock (AMICS) despite conflicting evidence regarding their effect on mortality. We aimed to ascertain the effect of early routine active percutaneous MCS versus control treatment on 6-month all-cause mortality in patients with AMICS. In this
-
How feasible is a cage-free solution for de novo coronary artery disease? Lancet (IF 98.4) Pub Date : 2024-09-02 Margaret B McEntegart, Ajay J Kirtane
-
Optimal patient and mechanical circulatory support device selection in acute myocardial infarction cardiogenic shock Lancet (IF 98.4) Pub Date : 2024-09-02 Jacob C Jentzer, Benjamin Hibbert
-
Mpox in eastern Democratic Republic of the Congo: challenges and prospects for vaccination Lancet (IF 98.4) Pub Date : 2024-09-02 Harry César Kayembe Ntumba, Bien-Aimé Makasa Mandja
-
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis Lancet (IF 98.4) Pub Date : 2024-09-01 Prof Pardeep S Jhund MBChB PhD, Atefeh Talebi PhD, Alasdair D Henderson PhD, Brian L Claggett PhD, Muthiah Vaduganathan MD, Akshay S Desai MD, Prof Carolyn S P Lam MBBS PhD, Prof Bertram Pitt MD, Prof Michele Senni MD, Prof Sanjiv J Shah MD, Prof Adriaan A Voors MD PhD, Prof Faiez Zannad MD, Prof Scott D Solomon MD, Prof John J V McMurray MD
Mineralocorticoid receptor antagonists (MRAs) reduce hospitalisations and death in patients with heart failure and reduced ejection fraction (HFrEF), but the benefit in patients with heart failure and mildly reduced ejection fraction (HFmrEF) or heart failure and preserved ejection fraction (HFpEF) is unclear. We evaluated the effect of MRAs in four trials that enrolled patients with heart failure
-
Mineralocorticoid receptor antagonists for every patient with heart failure Lancet (IF 98.4) Pub Date : 2024-09-01 Frans H Rutten, Amy Groenewegen
-
Is this the conclusive evidence for ticagrelor monotherapy in acute coronary syndromes? Lancet (IF 98.4) Pub Date : 2024-08-31 Giulio G Stefanini, Angelo Oliva
-
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials Lancet (IF 98.4) Pub Date : 2024-08-31 Prof Marco Valgimigli MD, Sung-Jin Hong MD, Felice Gragnano MD, Konstantina Chalkou PhD, Anna Franzone MD, Bruno R da Costa PhD, Usman Baber MD, Byeong-Keuk Kim MD, Yangsoo Jang MD, Prof Shao-Liang Chen MD, Prof Gregg W Stone MD, Prof Joo-Yong Hahn MD, Prof Stephan Windecker MD, Prof Michael C Gibson MD, Young Bin Song MD, Prof Zhen Ge MD, Prof Pascal Vranckx MD, Prof Shamir Mehta MD, Prof Hyeon-Cheol
Dual antiplatelet therapy (DAPT) for 12 months is the standard of care after coronary stenting in patients with acute coronary syndrome (ACS). The aim of this individual patient-level meta-analysis was to summarise the evidence comparing DAPT de-escalation to ticagrelor monotherapy versus continuing DAPT for 12 months after coronary drug-eluting stent implantation. A systematic review and individual
-
GLP-1 receptor agonists in heart failure: how far to expand use? Lancet (IF 98.4) Pub Date : 2024-08-30 Camilla Hage
-
Mpox threat: Pakistan must act now Lancet (IF 98.4) Pub Date : 2024-08-30 Saad Javed, Nimirta Sahitia, Eesha Yaqoob